AMGN240830C337500
- 0.26
- -0.61-70.11%
Amgen Newsroom
Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
A Closer Look At Amgen Inc.'s (NASDAQ:AMGN) Impressive ROE
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Dow Rallies 239 Points On Gains For Shares Of Intel, Dow
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Express News | Moody's Revises Amgen's Outlook To Stable From Negative
Intel, Amgen Share Losses Contribute To Dow's 100-Point Fall
BioMarin Appoints New Business Chief and R&D Head
FTC Says FDA Biosimilar Guidance Would Increase Competition, Lead to Lower Prices
Argus Research Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $360
Express News | Amgen Inc : Argus Research Raises Target Price to $360
Express News | Amgen Announces Availability Of Otezla In The US For Pediatric Use
Express News | Otezla® (Apremilast) Now Available in the U.S. for Moderate to Severe Pediatric Plaque Psoriasis
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks
Dow's 116-Point Rally Highlighted By Gains In Shares Of McDonald'S, Walt Disney
Caterpillar, Microsoft Share Losses Lead Dow's 100-Point Drop
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
These 10 Drugs Will Be Cheaper After Medicare Negotiations
US Drug Price Measure to Cut Costs by $7.5 Billion in 2026